iNKT can sense changes in the lipid metabolism of cancer cells and directly kill tumor cells through CD1d-mediated antigen recognition or target ligands on tumor or stressed cells through the expression of various NK activating receptors (e.g., NKG2D, NKp30, and NKp44) or tumor necrosis factor (TNF) receptors, subsequently driving cell death pathways through the release of cytotoxic granules (5, 7). This evidence concerns the gene SLAMF6 and neoplasm.